Nektar Therapeutics, a biopharmaceutical company, researches and develops drug candidates for cancer and auto-immune disease in the United States.
Excellent balance sheet and slightly overvalued.
Share Price & News
How has Nektar Therapeutics's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: NKTR has not had significant price volatility in the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: NKTR exceeded the US Pharmaceuticals industry which returned 11.9% over the past year.
Return vs Market: NKTR exceeded the US Market which returned 16.3% over the past year.
Price Volatility Vs. Market
How volatile is Nektar Therapeutics's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 month ago | Simply Wall StShould You Review Recent Insider Transactions At Nektar Therapeutics (NASDAQ:NKTR)?
2 months ago | Simply Wall StIs Nektar Therapeutics's (NASDAQ:NKTR) CEO Overpaid Relative To Its Peers?
2 months ago | Simply Wall StAre Investors Undervaluing Nektar Therapeutics (NASDAQ:NKTR) By 44%?
Is Nektar Therapeutics undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: NKTR ($21.85) is trading below our estimate of fair value ($50.82)
Significantly Below Fair Value: NKTR is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: NKTR is unprofitable, so we can't compare its PE Ratio to the US Pharmaceuticals industry average.
PE vs Market: NKTR is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate NKTR's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: NKTR is overvalued based on its PB Ratio (3.1x) compared to the US Pharmaceuticals industry average (3x).
How is Nektar Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 13 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: NKTR is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: NKTR is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: NKTR is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: NKTR's revenue (44.8% per year) is forecast to grow faster than the US market (9.4% per year).
High Growth Revenue: NKTR's revenue (44.8% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: NKTR is forecast to be unprofitable in 3 years.
How has Nektar Therapeutics performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: NKTR is currently unprofitable.
Growing Profit Margin: NKTR is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: NKTR is unprofitable, and losses have increased over the past 5 years at a rate of 3.4% per year.
Accelerating Growth: Unable to compare NKTR's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: NKTR is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (12.1%).
Return on Equity
High ROE: NKTR has a negative Return on Equity (-34.18%), as it is currently unprofitable.
How is Nektar Therapeutics's financial position?
Financial Position Analysis
Short Term Liabilities: NKTR's short term assets ($1.2B) exceed its short term liabilities ($124.0M).
Long Term Liabilities: NKTR's short term assets ($1.2B) exceed its long term liabilities ($214.7M).
Debt to Equity History and Analysis
Debt Level: NKTR is debt free.
Reducing Debt: NKTR has no debt compared to 5 years ago when its debt to equity ratio was 355.3%.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: NKTR has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if NKTR has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
What is Nektar Therapeutics's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate NKTR's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate NKTR's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if NKTR's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if NKTR's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of NKTR's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Howard Robin (67 yo)
Mr. Howard W. Robin has been the Chief Executive Officer and the President of Prime Holdings & Investments Inc. since July 2001. Mr. Robin has been the Chief Executive Officer and President of Nektar Thera ...
CEO Compensation Analysis
Compensation vs Market: Howard's total compensation ($USD9.94M) is above average for companies of similar size in the US market ($USD5.74M).
Compensation vs Earnings: Howard's compensation has been consistent with company performance over the past year.
|CEO, President & Director||13.58yrs||US$9.94m||0.13% |
|Senior VP||4.17yrs||US$7.49m||0.069% |
|Senior VP of Finance & Chief Accounting Officer||12.33yrs||US$1.92m||0.097% |
|Chief Research & Development Officer||0.83yr||US$7.27m||0.18% |
|Senior VP & Chief Commercial Officer||0.67yr||US$6.36m||no data|
|Senior VP||4.08yrs||no data||0.029% |
|Senior Vice President of Strategy & Corporate Affairs||1.58yrs||no data||no data|
|Senior VP & Executive Clinical Fellow||2.75yrs||no data||no data|
|Senior VP of Clinical Development & Head of Immunology Program||3.25yrs||no data||no data|
|Senior Vice President of Manufacturing||1.58yrs||no data||no data|
|VP and Head of Discovery & Research||2.17yrs||no data||no data|
|Senior Vice President & Head of Development||1.75yrs||no data||no data|
Experienced Management: NKTR's management team is considered experienced (2.5 years average tenure).
|CEO, President & Director||13.58yrs||US$9.94m||0.13% |
|Independent Director||1.92yrs||US$352.73k||no data|
|Independent Chairman of the Board||21.33yrs||US$385.93k||0.15% |
|Independent Director||10.5yrs||US$379.23k||0.096% |
|Lead Independent Director||1.58yrs||US$384.23k||0.12% |
|Independent Director||13yrs||US$361.23k||0.011% |
|Independent Director||2.92yrs||US$351.48k||0.0064% |
|Independent Director||0.67yr||US$548.11k||no data|
Experienced Board: NKTR's board of directors are considered experienced (6.7 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: NKTR insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 2.1%.
Nektar Therapeutics's company bio, employee growth, exchange listings and data sources
- Name: Nektar Therapeutics
- Ticker: NKTR
- Exchange: NasdaqGS
- Founded: 1990
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$3.889b
- Shares outstanding: 177.99m
- Website: https://www.nektar.com
Number of Employees
- Nektar Therapeutics
- 455 Mission Bay Boulevard South
- San Francisco
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|NKTR||NasdaqGS (Nasdaq Global Select)||Yes||Common Stock||US||USD||May 1994|
|ITH||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||May 1994|
|0UNL||LSE (London Stock Exchange)||Yes||Common Stock||GB||USD||May 1994|
|NKTR *||BMV (Bolsa Mexicana de Valores)||Yes||Common Stock||MX||MXN||May 1994|
Nektar Therapeutics, a biopharmaceutical company, researches and develops drug candidates for cancer and auto-immune disease in the United States. The company develops NKTR-181, a novel mu-opioid analgesic ...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/08/10 00:13|
|End of Day Share Price||2020/08/07 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.